Longmiao Hu

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

Juanjuan Feng, Zhengke Lian, Xinting Xia et al. · Acta Pharmaceutica Sinica B · 2022 · 62 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Identification of the Raf kinase inhibitor TAK‐632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3

Xiaofei Chen, Chunlin Zhuang, Yibin Ren et al. · British Journal of Pharmacology · 2019 · 57 citations · Full text

Medicine, Cell Biology, Pharmacology +12

<i>N</i>-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[<i>d</i>]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure–Activity Relationships, and in Vivo Efficacy

Hao Zhang, Lijuan Xu, Xia Qin et al. · Journal of Medicinal Chemistry · 2019 · 53 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells

Changying Shi, Jiamei Yang, Longmiao Hu et al. · Aging · 2020 · 46 citations · Full text

Medicine, Cancer Biology, Oncology +16

Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons

Yanan Liu, Longmiao Hu, Zhengzhen Wu et al. · Nature Communications · 2023 · 31 citations · Full text

Medicine, Immunology, Oncology +17